Logical Therapeutics raises cash for mid-stage NSAID trial

Logical Therapeutics has pulled in the first $10 million in a planned $16.9 million round, according to Xconomy, citing documents filed with the Securities and Exchange Commission. The company's president declined comment on the SEC filing, but several weeks ago the Waltham, MA-based developer revealed that it had begun a Phase IIb trial of a new form of naproxen, an NSAID pain therapy known to be very effective but one that has also been linked to a long list of side effects. Finding...